Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With Moderate to Severe Chronic Kidney Disease (CKD) With Iron Deficiency
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 years or greater
- Moderate to severe CKD not requiring dialysis (eGFR 15 - 45 ml/min/1.73 m2 by CKD-EPI)
- Absolute iron deficiency (serum ferritin <300ng/ml and Transferrin Saturation < 30%)
Exclusion Criteria:
- Hemoglobin concentrations > 13 g/dL
- Known disorder of iron homeostasis (e.g., hemochromatosis)
- Known gastrointestinal disorder (irritable bowel disease, inflammatory bowel disease)
- Known liver disease (ALT/AST or bilirubin > 3x normal)
- Serum phosphorus concentrations < 3.0 mg/dL
- Any known cause of anemia other than iron deficiency or CKD (e.g., sickle cell anemia)
- Symptomatic gastrointestinal bleeding within 12 weeks prior to the screening visit.
- Subjects receiving any form of renal replacement therapy including hemodialysis, peritoneal dialysis, or renal transplant.
- Pregnancy or lactation in female participants
- Severe anemia defined as a hemoglobin < 8.0 g/dL for males or a hemoglobin <7.0 g/dL for females.
- Receipt of erythropoiesis stimulating agents within 4 weeks of screening.
- Receipt of intravenous iron therapy within 8 weeks of screening.
- Blood transfusion within 4 weeks of screening
- Known allergies or severe adverse reactions to previous oral iron therapy
- Current use of oral phosphorus binders.
- Current use of an active vitamin D analog
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ferric citrate
Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.
|
Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.
Other Names:
|
|
Active Comparator: ferrous sulfate
Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day
|
Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Ferritin From Baseline to End of Treatment
Time Frame: Baseline and 12 weeks
|
The change in serum ferritin concentrations from the baseline of the study to the 12 week time point.
|
Baseline and 12 weeks
|
|
Change in Transferrin Saturation From Baseline to End of Treatment
Time Frame: Baseline and 12 weeks
|
The change in serum transferrin saturation from the baseline to the end of treatment
|
Baseline and 12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Hemoglobin From Baseline to End of Treatment
Time Frame: Baseline and 12 weeks
|
The change in hemoglobin concentrations from the baseline visit to the 12-week time point.
|
Baseline and 12 weeks
|
|
Change in Hepcidin From Baseline to the End of Treatment
Time Frame: Baseline and 12 weeks
|
The change in hepcidin concentrations from the baseline visit to the 12-week time point.
|
Baseline and 12 weeks
|
|
Change in Fibroblast Growth Factor 23 From Baseline to the End of Treatment
Time Frame: Baseline and 12 weeks
|
The change in fibroblast growth factor 23 concentrations from the baseline visit to the 12-week time point.
|
Baseline and 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Orlando M Gutierrez, MD, University of Alabama at Birmingham
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- F160318006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.